Amarin Corp
高管
查看带有其 14 名主要高管的组织结构图
Amarin Corp 搜索最多的简介
- Aaron Berg, President and Chief Executive Officer
- Oliver O'Connor, Independent Director
- Paul Cohen, Director
高管在Amarin Corp变化
- Peter Fishman 曾任 Principal Financial Officer and Principal Accounting Officer, 现升职为 Chief Financial Officer (新闻发布的2024十二月16号).
- Tom Reilly, Chief Financial Officer, 已经离开公司 (新闻发布的2024十月9号).
- Patrick Holt, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024六月5号).
创建提醒
跟踪 Amarin Corp 的高管变动
药店
Amarin Corp 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Amarin Corp 的最新新闻稿
- Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update | Amarin Corporation plc
- Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022 | Amarin Corporation plc
- NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales | Amarin Corporation plc
- REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo | Amarin Corporation plc
- Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl) | Amarin Corporation plc
- Press Releases | Amarin Corporation plc
- Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business | Amarin Corporation plc
- Amarin Appoints Tom Reilly as New Chief Financial Officer | Amarin Corporation plc
- Amarin Announces Appointment of New Directors and Board Leadership Changes | Amarin Corporation plc
- Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs | Amarin Corp
- View more press releases Close
通过电子邮件
